Montanova Capital, LLC, Averill Master Fund, Ltd., and Aaron Cowen filed Amendment No. 2 to Schedule 13G with the SEC on November 13, 2026, disclosing their beneficial ownership of Aura Biosciences, Inc. common stock as of September 30, 2026.

Key Highlights

  • Montanova Capital and Aaron Cowen each beneficially own 2,973,971 shares of Aura Biosciences common stock, representing 2.9% of the class.
  • Averill Master Fund, Ltd. directly holds 2,535,780 shares, representing 2.4% of the class.
  • All voting and dispositive power is shared across all three reporting persons, with zero sole voting or sole dispositive power reported by any party.
  • Holdings include pre-funded warrants with no expiration date and an exercise price of $0.00001 per share, subject to a 9.99% beneficial ownership cap on exercise.
  • The triggering event date is September 30, 2026, and the filing is designated Amendment No. 2.
  • All securities are directly owned by advisory clients of Montanova Capital, LLC, with none of those clients holding more than 5% of the common stock individually, according to the filing.

Montanova Capital and Cowen Disclose Shared Stake in Aura Biosciences via Schedule 13G Amendment

According to the filing, Montanova Capital, LLC, a Delaware-organized investment adviser, and Aaron Cowen each report beneficial ownership of 2,973,971 shares of Aura Biosciences, Inc. (NASDAQ:AURA) common stock, par value $0.00001 per share (CUSIP: 05153U107), equal to 2.9% of the outstanding class. Averill Master Fund, Ltd., a Cayman Islands entity, reports direct ownership of 2,535,780 shares, or 2.4% of the class. The filing identifies the event date as September 30, 2026.

The filing discloses that the reported shares include common stock that may be acquired upon the exercise of pre-funded warrants carrying no expiration date and an exercise price of $0.00001 per share. The warrants are subject to a limitation restricting exercise if, after giving effect to the exercise, the holders and their affiliates would beneficially own more than 9.99% of the outstanding common stock in the aggregate. The filing notes that this cap may be adjusted by written notice to the issuer, but that any increase above 9.99% (up to a maximum of 19.99%) would not take effect until the 61st day after such notice is delivered.

The filing states that all securities reported are directly owned by advisory clients of Montanova Capital, LLC, and that none of those advisory clients individually beneficially owns more than 5% of the common stock. All three reporting persons certify that the securities "were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer," according to the filing's certification language.

What Was Disclosed

Montanova Capital, Averill Master Fund, and Aaron Cowen filed a Schedule 13G amendment reporting combined shared beneficial ownership of up to 2,973,971 shares of Aura Biosciences common stock as of September 30, 2026, including shares underlying pre-funded warrants subject to ownership caps.